Strides Arcolab Limited (Strides) today announced that the Strides’ Annual Report 2009 has won the “Platinum” Award in the Pharma US$ 100m to US$ 1b category of the prestigious 2009 Vision Awards Annual Report Competition organised by the League of American Communications Professionals (LACP), USA.
The Strides Annual Report achieved a cumulative score of 97/100 on parameters such as first impression, report cover, letter to shareholders, report narrative, report financials, creativity, message clarity and information accessibility. Overall there were 4000 entries for the 2009 Vision Awards with submission from more than 25 countries.
The jury comprising of international communications expert observed that collectively they “found the report to be very engaging...a wonderful report narrative, excellent presentation and overall communication.” Christine Kennedy, LACP Managing Director, added, “The first impression presented by this annual report is very good while the cover and letter to shareholders are excellent and outstanding, respectively. The work is supported by a robust financial section that we believe is outstanding. We classify this entry as being amongst the best annual reports within its industry this year.”
The LACP was established in 2001 to create a forum within the public relations industry to facilitate discussion of best-in-class practices in public relations and recognizes exemplary communication capabilities.
Commenting on the award Mr. T S Rangan, Group CFO, Strides Arcolab Limited said, “We are delighted at receiving this honour from a reputed body like LACP which is widely recognized as an authority in assessing the quality of financial reporting. We would like to express our appreciation to Atherstone Investor Communications who partnered with us in developing the Report.”
About Strides Arcolab Limited:
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company’s website at www.stridesarco.com.